{
    "ticker": "XERS",
    "name": "Xeris Pharmaceuticals, Inc.",
    "description": "Xeris Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products for patients with chronic and rare diseases. Founded in 2005 and headquartered in Chicago, Illinois, Xeris leverages its proprietary formulation technology to create ready-to-use injectable medications that simplify treatment and enhance patient compliance. The company\u2019s lead product, Gvoke, is a glucagon injection designed to treat severe hypoglycemia in patients with diabetes. Gvoke is notable for its ease of use and is available in both prefilled syringe and autoinjector forms, making it accessible for emergency situations. Xeris is also working on additional products in its pipeline that address various medical needs, with a commitment to bringing forth solutions that improve the patient experience and outcomes. The company aims to transform the way injectable medications are delivered and administered, focusing on patient-centered solutions. With a talented team of professionals and strategic partnerships, Xeris is positioned to expand its market presence and enhance the quality of care for patients with complex medical conditions.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Chicago, Illinois, USA",
    "founded": "2005",
    "website": "https://www.xerispharma.com",
    "ceo": "Paul R. Edick",
    "social_media": {
        "twitter": "https://twitter.com/XerisPharma",
        "linkedin": "https://www.linkedin.com/company/xeris-pharmaceuticals/"
    },
    "investor_relations": "https://investors.xerispharma.com",
    "key_executives": [
        {
            "name": "Paul R. Edick",
            "position": "CEO"
        },
        {
            "name": "D. Scott McCarrel",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Injectable Medications",
            "products": [
                "Gvoke"
            ]
        }
    ],
    "seo": {
        "meta_title": "Xeris Pharmaceuticals, Inc. | Innovative Injectable Solutions",
        "meta_description": "Explore Xeris Pharmaceuticals, Inc., a leader in ready-to-use injectable medications for chronic and rare diseases. Learn about our innovative products and commitment to patient care.",
        "keywords": [
            "Xeris Pharmaceuticals",
            "Injectable Medications",
            "Diabetes Treatment",
            "Gvoke",
            "Chronic Diseases",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Xeris Pharmaceuticals known for?",
            "answer": "Xeris Pharmaceuticals is known for developing ready-to-use injectable medications, particularly Gvoke for treating severe hypoglycemia."
        },
        {
            "question": "Who is the CEO of Xeris Pharmaceuticals?",
            "answer": "Paul R. Edick is the CEO of Xeris Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Xeris Pharmaceuticals headquartered?",
            "answer": "Xeris Pharmaceuticals is headquartered in Chicago, Illinois, USA."
        },
        {
            "question": "What is Gvoke?",
            "answer": "Gvoke is a glucagon injection used to treat severe hypoglycemia in patients with diabetes."
        },
        {
            "question": "When was Xeris Pharmaceuticals founded?",
            "answer": "Xeris Pharmaceuticals was founded in 2005."
        }
    ],
    "competitors": [
        "AMGN",
        "PFE",
        "SNY",
        "REGN"
    ],
    "related_stocks": [
        "JNJ",
        "ABBV",
        "MRK",
        "BMY"
    ]
}